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Abstract
Background: The formation of acyl-CoA by the action of acyl-CoA synthetases plays a crucial role
in membrane lipid turnover, including the plasma membrane of erythrocytes. In human, five Acyl-
CoA Synthetase Long-chain (ACSL) genes have been identified with as many as 3 different transcript
variants for each.
Results: Acyl-CoA Synthetase Long-chain member 6 (ACSL6) is responsible for activation of long-
chain fatty acids in erythrocytes. Two additional transcript variants were also isolated from brain
and testis. We report the expression in reticulocytes of two new variants and of the one isolated
from brain. All three represented different spliced variants of a mutually exclusive exon pair. They
encode a slightly different short motif which contains a conserved structural domain, the fatty acid
Gate domain. The motifs differ in the presence of either the aromatic residue phenylalanine (Phe)
or tyrosine (Tyr). Based on homology, two new isoforms for the closely related ACSL1 were
predicted and characterized. One represented a switch of the Phe- to the Tyr-Gate domain motif,
the other resulted from the exclusion of both. Swapping of this motif also appears to be common
in all mammalian ACSL member 1 and 6 homologs.
Conclusion: We propose that a Phe to Tyr substitution or deletion of the Gate domain, is the
structural reason for the conserved alternative splicing that affects these motifs. Our findings
support our hypothesis that this region is structurally important to define the activity of these
enzymes.
Background
In mammals, long-chain acyl-CoA synthetases (ACSL) are
necessary for fatty acid degradation, phospholipid remod-
eling, and production of long acyl-CoA esters that regulate
various physiological processes. These enzymes play a cru-
cial role in plasma membrane phospholipid turnover in
erythrocytes, via the Lands pathway [1], as these cells lack
the capacity for de novo lipid synthesis.
In human, five ACSL genes have been identified with as
many as 3 different transcript variants for each. The two
recognized transcript variants for ACSL6 (formerly LACS5
[2]) were the only ones reported that represented spliced
forms of a mutually exclusive pair of exons encoding a
short highly conserved motif in the middle of the protein.
All other variants differed in the amino terminus and/or
the 5' UTR region. Whereas the detailed structure of mam-
malian ACSL has not been reported, the crystal structure
of a bacterial homologue of ACSL has established this
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motif at the proximity of the catalytic site of the enzyme,
defining the entry gate for the fatty acid substrate [3]. This
region, referred to as the Gate domain, is also involved in
the formation of a pocket, the "dead-end branch", in
which the fatty acid is locked during the formation of the
CoA ester bond [3]. The depth and width of the pocket
likely defines the substrate specificity of each of the iso-
forms. In the bacterial homologue, a tryptophan residue
of the Gate domain blocks the fatty acid channel and pre-
vents entry of the acyl to the catalytic site. Binding of ATP
to the nearby P-loop results in rotation of this residue and
opening of the channel [3]. Interestingly, mammalian
ACSLs do not have this tryptophan residue and another
aromatic residue, tyrosine or phenylalanine, is conserved
at a different position.
For human ACSL6, although the region containing the
Gate domain is alternatively spliced, the Gate domain
itself is conserved. In both variants a consensus sequence
can be defined as D-x4-(Y, F)-LPLAH-x2-E, and we postu-
lated that the substitution of a Y (variant 1) to F (variant
2) residue underlies the reason for the alternative splicing
of the Gate-domain region. In addition to the variant orig-
inally found in erythroid cells, ACSL6_v1, we now have
isolated 3 additional variants from cDNA of reticulocytes:
the spliced variant originally found in brain, ACSL6_v2,
and two new isoforms, ACSL6_v4 and v5. We also identi-
fied a fifth variant, ACSL6_v3, present in the GenBank
database, which had not previously been recognized as a
different spliced transcript. Based on protein similarity
between different members of the ACSL family we
hypothesized that the only known isoform of ACSL1 was
in fact one of the two possible versions of the Gate
domain. Indeed we were able to identify and isolate from
different tissues two new transcripts representing spliced
variants of this domain, ACSL1_v1 and v3. We provide
evidence that the two versions of the Gate domain, which
we define as the Y- or F-Gate depending on the Y to F res-
idue substitution, are evolutionary conserved. These dif-
ferent Gate versions are present in amphibian, fish, fly,
bird and plant. They can be the product of separate genes
in some organisms, e.g. plants, or be obtained by an alter-
native switching affecting ACSL1 and 6 in others, e.g.
mammals.
Results
Five isoforms of ACSL6
ACSL6 variant 1 and variant 2 (ACSL6_v1 and ACSL6_v2)
represent spliced variants of two mutually exclusive exons
(Figures 1, 2 and 5). Both exons code for a short motif of
26 residues which contain a highly conserved domain in
the ACSL family; D-x4-(F, Y)-LPLAH-x2-E (Figures 1 and
5B). In the description of the structure of the bacterial
homologue of ACSL, this region was shown to contain an
entry gate for the fatty acid substrate [3]. Therefore, we
will refer to this region as the F- or Y-Gate domain which
contains either a F or Y and the two exons as Ex(F) and
Ex(Y), respectively. ACSL6_v1 was originally isolated
from K562 cells [2] and ACSL6_v2 from brain [Gen-
Bank:AB020644.1]. We isolated both isoforms from sev-
eral other tissues (Table 1).
We identified an additional variant form of ACSL6, as
ACSL6_v3 [GenBank:BC047453.1]. ACSL6_v3 lacks the
first coding exon and represents a truncated amino termi-
nus isoform. An alternative 3'-splice site appears to be
present in exon 3 as it also lacks the second half of exon 3
(Figures 1 and 2). This alternative splicing event results in
removal of a predicted membrane spanning segment.
Moreover, both Ex(F) and Ex(Y) are skipped in this tran-
script variant which results in a product without the Gate
domain.
Two new variants of ACSL6 were identified that we pro-
pose to name ACSL6_v4 and ACSL6_v5 (Table 1). Both
were isolated from reticulocyte cDNA and they represent
spliced variants of ACSL6_v2 (Figures 2 and 5). ACSL6_v4
lacks the first half of Ex(F) which is the least conserved
region among all variants (Figures 2). The actual Gate
domain is encoded by the second half of either Ex(F) or
Ex(Y). Whereas a similar variation may be expected in
Ex(Y) of ACSL6_v1, we were not able to detect a truncated
version of Ex(Y) in a survey of 98 clones (see Methods).
Ex(F) appears to contain an alternative 3' acceptor splicing
site.
ACSL6_v5 contains an additional sequence of 45 bases
between exon 7 and 8 as compared to ACSL6_v2 (Figures
2 and 5). This element perfectly matched a portion of
intron 7 in the genomic sequence (NT_034772.5, posi-
tion 33739262–33739306). The insertion occurs at the 5'
donor splicing site of exon 7, position +1 of the last
codon, (E7)-G/CG-(E9). This event results in the in-frame
translation of an additional 15 residues at position T192
(Figure 2) and restoration of the GCG codon, (E7)-G/GG-
new exon-G\CG-(E9). We propose that this element con-
stitutes a new exon, exon 8.
Altogether, we have newly identified or confirmed five dif-
ferent forms of ACSL6 (Table 2) expressed by alternative
splicing as summarized in Figure 5.
ACSL6 forms dimers in the plasma membrane
As already mentioned, ACSL6_v3 lacks the putative
amino-terminal transmembrane segment that was pre-
dicted by several different analysis tools. Various topology
tools predict up to three transmembrane segments of
ACSL6, but most of these models are not consistent with
predictions for the other ACSL isoforms and are probably
not compatible with the domain organization of the pro-BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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Sequence alignment of the human acyl-CoA synthetases long-chain family members Figure 1
Sequence alignment of the human acyl-CoA synthetases long-chain family members. The succession of clear-
shaded blocks overlaid on the alignment represents the exon organization of the respective mRNA. Conserved residues are in 
bold. Position of the P-loop, Gate, A-box and Linker motifs is indicated. Y and F residues of the two alternative Gate domains 
are boxed and indicated with a star. Transmembrane spanning segments predicted with the highest score by TopoPrediction, 
SOSUI and TMHMM are underlined. For clarity, ACSL3 variant 1 and 2, and ACSL5 variant 2 and 3, which encode the same 
isoform, are annotated as ACSL3_v1v2 and ACSL5_v2v3, respectively. Alignment was performed with MUTALIN [14]. Protein 
length (residues): ACSL1_v1, 698; ACSL1_v2, 698; ACS3_v1v2, 720; ACSL4_v1, 670; ACSL4_v2, 711; ACSL5_v1, 739; 
ACSL5_v2v3, 683; ACSL6_v1, 722; ACSL6_v2, 722; ACSL6_v3, 622. GenBank accessions numbers are given in Table 2.
                    10        20        30        40        50        60        70        80        90       100 
                     |         |         |         |         |         |         |         |         |         | 
HsACSL6_v1  -----------------MLTFFLVSGGSLWLFVEFVLSLLEKMQTQEILRILRLPELGDLGQF-FRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNL
HsACSL6_v2  -----------------MLTFFLVSGGSLWLFVEFVLSLLEKMQTQEILRILRLPELGDLGQF-FRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNL
HsACSL6_v3  ---------------------------------………………………MQTQEILRILRLPELGDLGQF-FRSLSATTL---------------------------
HsACSL1_v2  ------------------------------------------MQAHELFRYFRMPELVDFRQY-VRTLPTNTLMGFGAFAALTTFWYATRPKPLKPPCDL
HsACSL5_v1  MDALKPPCLWRNHERGKKDRDSCGRKNSEPGSPHSLEALRDAAPSQGLNFLLLFTKMLFIFNFLFSPLPTPALICILTFGAAIFLWLITRPQPVLPLLDL
HsACSL5_v2v3----------------------------------------------…………………………MLFIFNFLFSPLPTPALICILTFGAAIFLWLITRPQPVLPLLDL
HsACSL3_v1v2-------------------------MNNHVSSKPSTMKLKHTINPILLYFIHFLISLYTILTYIPFYFFSESRQEKS--NRIKAKPVNSKPDSAYRSVN-
HsACSL4_v1  --------------------------------------------------------------------------………MAKRIKAKPTSDKPGSPYRSVT-
HsACSL4_v2  ------------------------------------MKLKLNVLTIILLPVHLLITIYSALIFIPWYFLTNAKKKNAMAKRIKAKPTSDKPGSPYRSVT-
       110       120       130       140       150       160       170       180       190       200       210 
         |         |         |         |         |         |         |         |         |         |         | 
LMQSEEVEDSGGARRSVIGSGPQLLTHYYDDARTMYQVFRRGLSISGNGPCLGFRKPKQPYQWLSYQEVADRAEFLGSGLLQHNCKACTDQFIGVFAQNRPEWIIVELAC
LMQSEEVEDSGGARRSVIGSGPQLLTHYYDDARTMYQVFRRGLSISGNGPCLGFRKPKQPYQWLSYQEVADRAEFLGSGLLQHNCKACTDQFIGVFAQNRPEWIIVELAC
--------DSGGARRSVIGSGPQLLTHYYDDARTMYQVFRRGLSISGNGPCLGFRKPKQPYQWLSYQEVADRAEFLGSGLLQHNCKACTDQFIGVFAQNRPEWIIVELAC
SMQSVEVAGSGGARRSALLDSDEPLVYFYDDVTTLYEGFQRGIQVSNNGPCLGSRKPDQPYEWLSYKQVAELSECIGSALIQKGFKTAPDQFIGIFAQNRPEWVIIEQGC
NNQSVGIE--GGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNGPCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELAC
NNQSVGIE--GGARKGVSQKNNDLTSCCFSDAKTMYEVFQRGLAVSDNGPCLGYRKPNQPYRWLSYKQVSDRAEYLGSCLLHKGYKSSPDQFVGIFAQNRPEWIISELAC
SLDGLASVLYPGCDTLDKVFTYAKNKFKNKRLLGTREVLNEEDEVQPNGKIFKKVILGQ-YNWLSYEDVFVRAFNFGNGLQMLGQK--PKTNIAIFCETRAEWMIAAQAC
HFDSLAVIDIPGADTLDKLFDHAVSKFGKKDSLGTREILSEENEMQPNGKVFKKLILGN-YKWMNYLEVNRRVNNFGSGLTALGLK--PKNTIAIFCETRAEWMIAAQTC
HFDSLAVIDIPGADTLDKLFDHAVSKFGKKDSLGTREILSEENEMQPNGKVFKKLILGN-YKWMNYLEVNRRVNNFGSGLTALGLK--PKNTIAIFCETRAEWMIAAQTC
       220       230       240       250       260       270       280       290       300       310       320 
         |         |         |         |         |         |         |         |         |         |         | 
YTYSMVVVPLYDTLGPGAIRYIINTADISTVIVDKPQKAVLLLEHVERKETPGLKLIILMDPFEEALKERGQKCGVVIKSMQAVEDCGQENHQAPVP---PQPDDLSIVC
YTYSMVVVPLYDTLGPGAIRYIINTADISTVIVDKPQKAVLLLEHVERKETPGLKLIILMDPFEEALKERGQKCGVVIKSMQAVEDCGQENHQAPVP---PQPDDLSIVC
YTYSMVVVPLYDTLGPGAIRYIINTADISTVIVDKPQKAVLLLEHVERKETPGLKLIILMDPFEEALKERGQKCGVVIKSMQAVEDCGQANHQAPVP---PQPDDLSIVC
FAYSMVIVPLYDTLGNEAITYIVNKAELSLVFVDKPEKAKLLLEGVENKLIPGLKIIVVMDAYGSELVERGQRCGVEVTSMKAMEDLGRANRRKPKP---PAPEDLAVIC
YTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKALVLIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVP---PSPEDLSVIC
YTYSMVAVPLYDTLGPEAIVHIVNKADIAMVICDTPQKALVLIGNVEKGFTPSLKVIILMDPFDDDLKQRGEKSGIEILSLYDAENLGKEHFRKPVP---PSPEDLSVIC
FMYNFQLVTLYATLGGPAIVHALNETEVTNIITSKELLQTKLKDIV--SLVPRLRHIITVDGKPPTWSEFPK--GIIVHTMAAVEALGAKASMENQPHSKPLPSDIAVIM
FKYNFPLVTLYATLGKEAVVHGLNESEASYLITSVELLESKLKTAL--LDISCVKHIIYVDNKAINKAEYPE--GFEIHSMQSVEELGSNPENLGIPPSRPTPSDMAIVM
FKYNFPLVTLYATLGKEAVVHGLNESEASYLITSVELLESKLKTAL--LDISCVKHIIYVDNKAINKAEYPE--GFEIHSMQSVEELGSNPENLGIPPSRPTPSDMAIVM
       330       340       350       360       370       380       390       400       410       420       430 
P-loop  |         |         |         |     Gate          |         |         |         |         |         | 
FTSGTTGNPKGAMLTHGNVVADFSGFLKVTESQWAPTCADVHISYLPLAHMFERMVQSVVYCHGGRVGFFQGDI--------RLLSDDMKALCPTIFPVVPRLLNRMYD-
FTSGTTGNPKGAMLTHGNVVADFSGFLKVTEKVIFPRQDDVLISFLPLAHMFERVIQSVVYCHGGRVGFFQGDI--------RLLSDDMKALCPTIFPVVPRLLNRMYD-
FTSGTTGNPKGAMLTHGNVVADFSGFLKVTE-----------------------------------------GDI--------RLLSDDMKALCPTIFPVVPRLLNRMYD-
FTSGTTGNPKGAMVTHRNIVSDCSAFVKATENTVNPCPDDTLISFLPLAHMFERVVECVMLCHGAKIGFFQGDI--------RLLMDDLKVLQPTVFPVVPRLLNRMFD-
FTSGTTGDPKGAMITHQNIVSNAAAFLKCVEHAYEPTPDDVAISYLPLAHMFERIVQAVVYSCGARVGFFQGDI--------RLLADDMKTLKPTLFPAVPRLLNRIYD-
FTSGTTGDPKGAMITHQNIVSNAAAFLKCVEHAYEPTPDDVAISYLPLAHMFERIVQAVVYSCGARVGFFQGDI--------RLLADDMKTLKPTLFPAVPRLLNRIYD-
YTSGSTGLPKGVMISHSNIIAGITG---MAERIPELGEEDVYIGYLPLAHVLELSAELVCLSHGCRIGYSSPQTLADQSKIKKGSKGDTSMLKPTLMAAVPEIMDRIYKS
YTSGSTGRPKGVMMHHSNLIAGMTG---QCERIPGLGPKDTYIGYLPLAHVLELTAEISCFTYGCRIGYSSPLTLSDQSKIKKGSKGDCTVLKPTLMAAVPEIMDRIYKS
YTSGSTGRPKGVMMHHSNLIAGMTG---QCERIPGLGPKDTYIGYLPLAHVLELTAEISCFTYGCRIGYSSPLTLSDQSKIKKGSKGDCTVLKPTLMAAVPEIMDRIYKS
       440       450       460       470       480       490       500       510       520       530       540 
         |         |         |         |         |         |         |         |    A-Box|         |         | 
KIFSQAN--TPLKRWLLEFAAKRKQAEVRSGIIRNDSIWDELFFNKIQASLGGCVRMIVTGAAPASPTVLGFLRAALGCQVYEGYGQTECTAGCTFTTPGDWTSGHVGAP
KIFSQAN--TPLKRWLLEFAAKRKQAEVRSGIIRNDSIWDELFFNKIQASLGGCVRMIVTGAAPASPTVLGFLRAALGCQVYEGYGQTECTAGCTFTTPGDWTSGHVGAP
KIFSQAN--TPLKRWLLEFAAKRKQAEVRSGIIRNDSIWDELFFNKIQASLGGCVRMIVTGAAPASPTVLGFLRAALGCQVYEGYGQTECTAGCTFTTPGDWTSGHVGAP
RIFGQAN--TTLKRWLLDFASKRKEAELRSGIIRNNSLWDRLIFHKVQSSLGGRVRLMVTGAAPVSATVLTFLRAALGCQFYEGYGQTECTAGCCLTMPGDWTAGHVGAP
KVQNEAK--TPLKKFLLKLAVSSKFKELQKGIIRHDSFWDKLIFAKIQDSLGGRVRVIVTGAAPMSTSVMTFFRAAMGCQVYEAYGQTECTGGCTFTLPGDWTSGHVGVP
KVQNEAK--TPLKKFLLKLAVSSKFKELQKGIIRHDSFWDKLIFAKIQDSLGGRVRVIVTGAAPMSTSVMTFFRAAMGCQVYEAYGQTECTGGCTFTLPGDWTSGHVGVP
NVMNKVSEMSSFQRNLFILAYNYKMEQISKG--RNTPLCDSFVFRKVRSLLGGNIRLLLCGGAPLSATTQRFMNICFCCPVGQGYGLTESAGAGTISEVWDYNTGRVGAP
NVMSKVQEMNYIQKTLFKIGYDYKLEQIKKG--YDAPLCNLLLFKKVKALLGGNVRMMLSGGAPLSPQTHRFMNVCFCCPIGQGYGLTESCGAGTVTEVTDYTTGRVGAP
NVMSKVQEMNYIQKTLFKIGYDYKLEQIKKG--YDAPLCNLLLFKKVKALLGGNVRMMLSGGAPLSPQTHRFMNVCFCCPIGQGYGLTESCGAGTVTEVTDYTTGRVGAP
       550       560       570       580       590       600       610       620       630       640       650 
         |         |         |         |         |         |        |       Linker       |         |         | 
LPCNHIKLVDVEELNYWACKG---EGEICVRGPNVFKGYLKDPDRTKE--ALDSDG--WLHTGDIGKWLPAGTLKIIDRKKHIFKLAQGEYVAPEKIENIYIRSQPVAQI
LPCNHIKLVDVEELNYWACKG---EGEICVRGPNVFKGYLKDPDRTKE--ALDSDG--WLHTGDIGKWLPAGTLKIIDRKKHIFKLAQGEYVAPEKIENIYIRSQPVAQI
LPCNHIKLVDVEELNYWACKG---EGEICVRGPNVFKGYLKDPDRTKE--ALDSDG--WLHTGDIGKWLPAGTLKIIDRKKHIFKLAQGEYVAPEKIENIYIRSQPVAQI
MPCNLIKLVDVEEMNYMAAEG---EGEVCVKGPNVFQGYLKDPAKTAE--ALDKDG--WLHTGDIGKWLPNGTLKIIDRKKHIFKLAQGEYIAPEKIENIYMRSEPVAQV
LACNYVKLEDVADMNYFTVNN---EGEVCIKGTNVFKGYLKDPEKTQE--ALDSDG--WLHTGDIGRWLPNGTLKIIDRKKNIFKLAQGEYIAPEKIENIYNRSQPVLQI
LACNYVKLEDVADMNYFTVNN---EGEVCIKGTNVFKGYLKDPEKTQE--ALDSDG--WLHTGDIGRWLPNGTLKIIDRKKNIFKLAQGEYIAPEKIENIYNRSQPVLQI
LVCCEIKLKNWEEGGYFNTDKPHPRGEILIGGQSVTMGYYKNEAKTKADFFEDENGQRWLCTGDIGEFEPDGCLKIIDRKKDLVKLQAGEYVSLGKVEAALKNLPLVDNI
LICCEIKLKDWQEGGYTINDKPNPRGEIVIGGQNISMGYFKNEEKTAEDYSVDENGQRWFCTGDIGEFHPDGCLQIIDRKKDLVKLQAGEYVSLGKVEAALKNCPLIDNI
LICCEIKLKDWQEGGYTINDKPNPRGEIVIGGQNISMGYFKNEEKTAEDYSVDENGQRWFCTGDIGEFHPDGCLQIIDRKKDLVKLQAGEYVSLGKVEAALKNCPLIDNI
       660       670       680       690       700       710       720       730       740       750       760 
         |         |         |         |         |         |         |         |         |         |         | 
YVHGDSLKAFLVGIVVPDPEVMPSWAQKRGIEGTYADLCTNKDLKKAILEDMVRLGKESGLHSFEQVKAIHIHSDMFSVQNGLLTPTLKAKRPELREYFKKQIEELYSISM
YVHGDSLKAFLVGIVVPDPEVMPSWAQKRGIEGTYADLCTNKDLKKAILEDMVRLGKESGLHSFEQVKAIHIHSDMFSVQNGLLTPTLKAKRPELREYFKKQIEELYSISM
YVHGDSLKAFLVGIVVPDPEVMPSWAQKRGIEGTYADLCTNKDLKKAILEDMVRLGKESGLHSFEQVKAIHIHSDMFSVQNGLLTPTLKAKRPELREYFKKQIEELYSISM
FVHGESLQAFLIAIVVPDVETLCSWAQKRGFEGSFEELCRNKDVKKAILEDMVRLGKDSGLKPFEQVKGITLHPELFSIDNGLLTPTMKAKRPELRNYFRSQIDDLYSTIKV
FVHGESLRSSLVGVVVPDTDVLPSFAAKLGVKGSFEELCQNQVVREAILEDLQKIGKESGLKTFEQVKAIFLHPEPFSIENGLLTPTLKAKRGELSKYFRTQIDSLYEHIQD
FVHGESLRSSLVGVVVPDTDVLPSFAAKLGVKGSFEELCQNQVVREAILEDLQKIGKESGLKTFEQVKAIFLHPEPFSIENGLLTPTLKAKRGELSKYFRTQIDSLYEHIQD
CAYANSYHSYVIGFVVPNQKELTELARKKGLKGTWEELCNSCEMENEVLKVLSEAAISASLEKFEIPVKIRLSPEPWTPETGLVTDAFKLKRKELKTHYQADIERMYGRK
CAFAKSDQSYVISFVVPNQKRLTLLAQQKGVEGTWVDICNNPAMEAEILKEIREAANAMKLERFEIPIKVRLSPEPWTPETGLVTDAFKLKRKELRNHYLKDIERMYGGK
CAFAKSDQSYVISFVVPNQKRLTLLAQQKGVEGTWVDICNNPAMEAEILKEIREAANAMKLERFEIPIKVRLSPEPWTPETGLVTDAFKLKRKELRNHYLKDIERMYGGKBMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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tein. Based on the activity of the enzyme, both the ATP-
binding site and the C-terminus domain need to face the
cytosol. However, in several predictions, these regions
would be exposed to the wrong and/or opposite sides of
the membrane.
ACSL6_v1, v2 and v3 were cloned and expressed as hexa-
histidine fusion proteins in E. coli (see Methods). Despite
that the predicted structure precludes a proper insertion of
variant 3 in a membrane lipid bilayer, product of variant
3 was found in a membrane fraction, as was v1 and v2
product (Figure 3A and data not shown). It can be argued
that ACSL6_v3 was not inserted but associated with the
membrane as was suggested for the E. coli FadD homolog
[4] and rat ACSL4 [5]. Alternatively, another region of the
protein may have assured anchoring to the membrane.
When analyzed on denaturing SDS polyacrylamide gel
(see Methods), each of the three isoforms appeared as two
species of apparent molecular mass of 75–80 kDa and 130
kDa (Figure 3A and data not shown). A slightly lower
apparent molecular mass was observed for the shorter var-
iant ACSL6_v3. The predicted molecular mass was 80 kDa
for variants 1 and 2 and 72 kDa for v3. Thus, as it has been
established for the bacterial homologue [3], human
ACSL6 appeared to be a dimer. With a protein extract of
the erythroleukaemic cell line K562, an ACSL6 antibody
recognized three major species at 75 kDa and at 130 kDa
(Figure 3B). The two bands migrating at the expected posi-
tion for a monomer probably represent isoforms of
slightly different molecular mass (Table 1).
Table 1: Transcript variants for ACSL1 and ACSL6 identified in various tissues. Variants for ACSL1 and 6 were identified from cDNAs 
by PCR amplification of the Gate-domain region (see Methods). The number of clones representing each of the variants found in the 
population of sequenced clones is given as a ratio and is shown under each respective variant.
ACSL11 ACSL62
CD34+ cells v2 – v3 (34/35 – 1/35) v1 – v2 (19/22 – 3/22)
Reticulocytes not detected v1 – v2 – v4 – v5 (3/8 – 4/8 – 1/8) – (2/4)3
K-562 cells v1 – v2 – v3 (1/11)3 – (29/30 – 1/30) v1 – v2 – v4 (24/26 – 1/26 – 1/26)
1ACSL1_v1 was found in placenta (1/10). ACSL1_v2 was found in fetal blood liver (11/11) and placenta (9/10).
2ACSL6_v3 could not be found by PCR screening of an additional 38 clones.
3Clones identified by RACE-PCR in an independent experiment.
Details of the sequence differences of the five human ACSL6 isoforms Figure 2
Details of the sequence differences of the five human ACSL6 isoforms. The Y and F residues of the Gate domains are 
boxed. Position of the first and last residues shown is indicated on the left and right, respectively. Note that only the Gate-
domain region of ACSL6_v4 is known. A predicted transmembrane spanning segment at the amino-terminus is shown under-
lined. The inserted sequence in between Exon 7 and Exon 9 of variant 5, annotated as Exon 8, is shown double-underlined.
Hs.ACSL6_v1  (45)  QFFRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNLLMQSEEVEDSGGARRSVI (100) 
Hs.ACSL6_v2  (45)  QFFRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNLLMQSEEVEDSGGARRSVI (100) 
Hs.ACSL6_v3  (20)  QFFRSLSATTL-----------------------------------DSGGARRSVI (40) 
Hs.ACSL6_v5  (20)  QFFRSLSATTLVSMGALAAILAYWFTHRPKALQPPCNLLMQSEEVEDSGGARRSVI (75)
Hs.ACSL6_v1  (206)  LGPGAIRYIINT---------------ADISTVIVDKPQK    (230) 
Hs.ACSL6_v2  (206)  LGPGAIRYIINT---------------ADISTVIVDKPQK    (230) 
Hs.ACSL6_v3  (146)  LGPGAIRYIINT---------------ADISTVIVDKPQK    (170) 
Hs.ACSL6_v5  (181)  LGPGAIRYIINTGLSCQEGASATASTQADISTVIVDKPQK    (220)
          Exon 7      Exon 8     Exon 9
Hs.ACSL6_v1   (331)  SQWAPTCADVHISYLPLAHMFERMVQ    (356) 
Hs.ACSL6_v2   (331)  KVIFPRQDDVLISFLPLAHMFERVIQ    (356) 
Hs.ACSL6_v3   (270)  --------------------------     (270) 
Hs.ACSL6_v4   (?)    -------DDVLISFLPLAHMFERVIQ    (?) 
Hs.ACSL6_v5   (321)  KVIFPRQDDVLISFLPLAHMFERVIQ    (360)BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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Identification of new ACSL1 transcript variants
By sequence inspection of the Gate-domain motifs, we
noted that only two isoforms of ACSL, ACSL1 and
ACSL6_v2, of the 8 known isoforms (ACSL1, ACSL3,
ACSL4_v1 and _v2, ACSL5_v1 and v2/v3; ACSL6_v1 and
_v2) had an aromatic residue F instead of a Y (Figure 1).
We also noted that alternative splicing of ACSL6 resulted
in a F to Y substitution (Figures 2 and 5). Given that the
other conserved residues were not affected by this event,
we predicted the presence of spliced variants of ACSL1.
In human, mouse, and chimpanzee the exon encoding the
Y-Gate domain of ACSL6_v1 is downstream of the exon
encoding the F-Gate domain of ACSL6_v2 (Figure 4 and
not shown). The only reported ACSL1 isoform contains
the F-Gate domain, coded by exon 10. We identified a
potential new exon encoding a Y-Gate domain in the
intronic sequence downstream of ACSL1  exon 10 of
human, and exon 11 of mouse and chimpanzee (Figure 4
and not shown). As described in Methods, we surveyed
the Gate-domain motifs of human ACSL1 by PCR cDNAs
from various tissues. In addition to the known ACSL1 var-
iant containing the F-Gate domain, re-annotated
ACSL1_v2, we identified a variant with a Y-Gate domain
in placenta and K562 cells, ACSL1_v1, and a variant with-
out a Gate domain in CD34 positive cells and K562 cells,
ACSL1_v3 (Table 1 and Figure 5). From sequence inspec-
tion, it appeared that the other three ACSL members,
ACSL3, 4 and 5 can only encode a Y-Gate domain (see
Discussion).
The fatty acid gate domains of human ACS
An amino acid sequence comparison of the four different
families of human acyl-CoA synthetase proteins (Short,
Medium, Long and Very-long chain) revealed major dif-
ferences in the Gate-domain motifs. A consensus motif for
Short and Medium chain appears to be D-x6-D-x-G-W, in
which W might represent the gating residue (Figure 6).
Long and Very-long chain ACS shared the Gate-domain
motif D-x5-LPL-x-H in common but the conserved Y resi-
due (F for some variants) found at the -1 position of the
LPL-x-H motif for Long chain, Y-LPL-x-H, is shifted to
another position for the Very-long chain ACS, x-LPL-Y-H.
The conserved Linker motif [6] also supports the division
between Short-Medium and Long-Very-long. Long and
Very-long ACS, with the exception of human lipidosin or
bubblegum (BG1; see footnote Figure 6), contain an
Aspartate residue while the Short and Medium ACS have
a Glycine. As previously proposed [3], substitution of an
Asp to a Gly might introduce enough flexibility in this
region to allow two different conformations of the C-ter-
minus domain. Of the eleven putative ACS long-chain
plant homologues, two had no detectable activity and
were excluded from the ACS long-chain plant family [7].
Although all eleven showed a very high degree of similar-
ity to each other, only the nine active isoforms have Gate
and Linker consensus motifs for long-chain (Figure 7).
The other two lack an aromatic residue at the -1 position
of the LPL-x-H motif and had a Gly residue instead of an
Asp in their Linker motif.
Discussion
The mechanism by which Short, Medium, Long and Very-
long chain acyl-CoA synthetases achieve substrate specifi-
city is poorly understood. In spite of their high degree of
similarity and highly conserved structural domains,
length and degree of un-saturation of the fatty acid sub-
strates are being discriminated. Of particular interest is a
specific functional region in the bacterial protein that con-
tains the so called Gate domain [3]. In absence of ATP, an
aromatic residue, tryptophan, of the Gate domain blocks
the fatty acid tunnel and as such, the access of the fatty
acid to the active site. Upon binding of ATP to the nearby
P-loop, a conformational change induces rotation of this
residue and the opening of the channel. The hydrophilic
Detection of ACSL6 isoforms in E. coli (A) and in human  K562 cells (B) Figure 3
Detection of ACSL6 isoforms in E. coli (A) and in 
human K562 cells (B). A: vector (1, 2, 3); ACSL6_v2 (4, 5, 
6); ACSL6_v3 (7, 8, 9). Crude extract (1, 4, 7); Soluble frac-
tion (2, 5, 8); Membrane fraction (3, 6, 9). Detection per-
formed with Pierce INDIA HIS-antibody. Protein ladder 
standard is shown on the right (top to bottom: 250-150-100-
75 kDa). Proteins carried a hexahistidine-tag at their amino-
terminus (see Methods). B: Total protein extract of K562 
cells. Detection performed with a peptide raised antibody 
against ACSL6.
A
BBMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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Genomic and amino acid sequences of the gate-domain region of human ACSL6 and ACSL1 Figure 4
Genomic and amino acid sequences of the gate-domain region of human ACSL6 and ACSL1. A and B: Sequence 
of exons and introns of human ACSL6 (A) and ACSL1 (B) are represented by capitalized and small italics letters, respectively. 
The F and Y residues of the Gate domain of variant 2 and 1, respectively, are boxed. C: Amino acids alignment of the Gate-
domain motifs for known and predicted spliced variants. Highly conserved residues are shaded. Position of the first and last 
residues shown is indicated on the left and right, respectively. Abbreviations are: Hs, Homo sapiens; Ms, Mus musculus; Pt, Pan 
troglodytes.
variant 2
variant 1
variant 2
variant 1
A 
………cccactgacgctgcgacctaacactccgcttcctatgctgccctgtctctctcttctttctgcacctt 
ccccctccctctctctctccctctctctctcatttcttctctctttcatctcacctctctctctgtcctca 
ccactcccattcccctccccctcttcctgtttaccctccaggaccattttctctttattgttttatgattc 
tcttgtcgtcttcctgtcagtgtttctttcctttctgtctcccatgcccgtcgcctgcagAAAGTGATCTT 
 K  V  I  F 
TCCGAGACAGGACGATGTGCTCATCTCCTTCCTGCCTCTGGCTCACATGTTTGAGAGAGTAATCCAGgtaa 
  P  R  Q  D  D  V  L  I  S  F  L  P  L  A  H  M  F  E  R  V  I  Q 
gacacccacctgactgaccgggccttgcctgggctccttcttttttcttacagAGTCAGTGGGCTCCCACT
         S  Q  W  A  P  T 
TGTGCGGATGTGCACATTTCCTATTTGCCTTTAGCACACATGTTTGAGCGAATGGTGCAGgtaaggccctg 
 C  A  D  V  H  I  S  Y  L  P  L  A  H  M  F  E  R  M  V  Q 
gcatcagggaggcacactctgtgcctagaacccataaccctagcgggtgtcacttgtcactggtggcatga 
agtaggaccaaactgccctgtcctcagaaggtaccataggggtcagagggctcagaggactttagccaccc 
cacttgtccctcctgggagcattgttccagggaagcccccaggcctgccctgtcttacccatggacac……… 
B
………tttactcggagtcttttttttttaattttattattattatactttaagttttagggtgcatgtgcac 
aacgtgcaggtgtgttacatatgtgtacatgtgccatgctggtgtgctgcacccataaacttgtcattta 
gcattaggtatatctcctaatgctatccctcccccctccccctaccccacaaccgtccctggtgtgcgat 
gttccccttcactgggagtcttaatgcttttctgccttgctggtgtctttgcttacagAATACAGTCAAT 
                                                           N  T  V  N  
CCTTGCCCAGATGATACTTTGATATCTTTCTTGCCTCTCGCCCATATGTTTGAGAGAGTTGTAGAGgtag
 P  C  P  D  D  T  L  I  S  F  L  P  L  A  H  M  F  E  R  V  V  E 
gcatttaattttgttttccttgcttgtttgtgtatgttctgctaagttgttgtgttttacagAAAGCACTT
                                                               K  A  L 
CCCTTGAGTGCCAGTGACACACACATTTCATATTTACCACTTGCTCACATTTATGAACAGTTATTGAAGgt 
 P  L  S  A  S  D  T  H  I  S  Y  L  P  L  A  H  I  Y  E  Q  L  L  K  
aagtgtggcgtgcggactgtcatccctatagagaattctctgctcagccccgttttagaaatggtgcagat 
tatttgaaagaatataaattctttttctgagtatgaacaggatactggaatttaatcactcattttaaaat 
taggagttcagacttttgaaggatactaatgtggacatgagtccagaaaaaccaactataaaggtaaa……… 
C  
Hs.ACSL6_v1    (331)  SQWAPTCADVHISYLPLAHMFERMVQ   (356) 
Mm.ACSL6_v1    (331)  SQWAPTCADVHFSYLPLAHMFERMVQ   (356) 
Pt.ACSL6_v1    (331)  SQWAPTCADVHISYLPLAHMFERMVQ   (356) 
Hs.ACSL1_v1    (306)  KALPLSASDTHISYLPLAHIYEQLLK   (331) 
Mm.ACSL1_v1    (306)  SALTLNASDTQISYLPLAHMYEQQLQ   (331) 
Pt.ACSL1_v1    (306)  KALPLSASDTHISYLPLAHMYEQLLK   (331) 
Hs.ACSL6_v2    (331)  KVIFPRQDDVLISFLPLAHMFERVIQ   (356) 
Mm.ACSL6_v2    (331)  KVIFPRQDDVLISFLPLAHMFERVIQ   (356) 
Pt.ACSL6_v2    (331)  KVIFPRQDDVLISFLPLAHMFERVIQ   (356) 
Hs.ACSL1_v2    (306)  NTVNPCPDDTLISFLPLAHMFERVVE   (331) 
Mm.ACSL1_v2    (306)  SAFIASTDDVLISFLPLAHMFETVVE   (331) 
Pt.ACSL1_v2    (306)  NTVNPCPDDTLISFLPLAHMFERVVE   (331) BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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head group of the fatty acid reaches the catalytic site while
the hydrophobic tail is bent into the dead-end branch.
The depth and width of the pocket formed by the Gate
domain is a tight fit for the preferred substrates of the
enzyme [3]. The tryptophan is not conserved in mamma-
lian ACSL. As described in this study, expression of differ-
ent Gates with substitutions of an aromatic residue
(tyrosine to phenylalanine) might achieve different gating
and selectivity properties toward different substrates.
Measure of the substrate specificity of those membrane-
bound enzymes is complicated by differences in substrate
availability of the different fatty acids in the various pools
in the lipid bilayer, and by the necessary utilization and/
or removal of the acyl-CoA product (which is inhibitory
and detergent in nature). Although enzyme activities have
been assessed in E. coli, we found that both human and rat
ACSL6 accumulated in inclusion bodies when over-
expressed. The small fraction of proteins recovered in the
lysate was purified to various degrees and assayed in Tri-
ton X-100 micelles [8]. While we can measure acyl-CoA
formation of isoforms expressed in E. coli we refrain from
defining enzymatic activity (Km and Vmax) for different
fatty acids in this system, as these data would not neces-
sarily reflect the specificity of these isoforms in the mam-
malian plasma membrane, and therefore not add to a
better understanding of the actions of these proteins. The
activated fatty acyl groups generated in the red cell mem-
brane by ACSL6 are bound or processed by the other pro-
teins in the Lands pathway affecting the activity of ACSL6.
In addition, lipid-protein interactions will affect the activ-
ity of these isoforms precluding the determination of
proper enzyme kinetics in an artificial detergent rich lipid
environment as reported [8]. Therefore, we argue that
enzymatic characterization of the different isoforms,
homo- and hetero-dimers, in the plasma membrane with
proper lipid/protein and, lipid/lipid interactions affecting
enzyme activity will ultimately be essential and necessary
to understand the selectivity of this process in lipid and
protein acylation. The characterization of the different iso-
forms present in a plasma membrane defines the first step
in this process.
The validity to compare the bacterial homologue with the
human forms is supported by the evolutionary conserva-
tion of the Gate-domain motif in invertebrates and verte-
brates (Figure 7). In mammals, two members, ACSL
member 1 and 6, can produce the two different Gate
domains by alternative splicing. Sequence inspection of
the other three ACSL genes, ACSL3, 4 and 5, strongly sup-
ports the prediction that they can only encode one type of
Gate domain, Y-Gate. Thus, the F-Gate is specific for
ACSL1 and 6. The conservation of the aromatic residue,
Phe or Tyr, in all forms of ACSL supports our hypothesis
that this region is structurally important to define the
activity of these enzymes [9].
ACSL1 mRNA was highly expressed in erythroid progeni-
tors, CD34 positives cells, but it could not be detected by
Northern-blot [2] or by RT-PCR in reticulocytes (Table 1).
However, it was detected in the nucleated dividing eryth-
roleukaemic cell line K562. ACSL1_v2 (F-Gate) and v3
(no Gate) were detected in erythroid progenitor cells but
v1 (Y-Gate) was not. ACSL6_v1 and v2 were found in both
precursors cells and reticulocytes but v3 was not. Perhaps,
in early stages of erythroid differentiation, ACSL1 might
have function(s) not requiring a Gate domain while
ACSL6 must have both types. ACSL6 variant 3, which
lacks the Gate domain and has been isolated from human
testis, was not detected in the tissues we surveyed. The
existence of ACSL6_v3 [alternative splice site in exon 3
and exclusion of both Ex(Y) and Ex(F)] is supported by
the fact that variant 3 of ACSL1, variant 2 [Gen-
Bank:AAH57770] of SLC27A2 [GenBank:NP_003636.1]
(Figure 6), and short form 1 of GR-LACS [9] also lack the
Gate-domain region. Moreover, an identical alternative
splicing event affecting exon 3 was identified in cDNA iso-
lated from bone marrow of an individual with acute eosi-
Table 2: Human acyl-CoA synthetase long-chain family member isoforms.
Gene Y-Gate
D-x4-Y-LPLAH-x2-E
F-Gate
D-x4-F-LPLAH-x2-E
No Gate
ACSL1 variant 1/DQ083029 variant 2/NM_001995.2 variant 3/DQ083028
ACSL3 variant 1/NM_004457.3
variant 2/NM_203372.1
ACSL4 variant 1/NM_004458.1
variant 2/NM_022977.1
ACSL5 variant 1/NM_016234.3
variant 2/NM_203379.1
variant 3/NM_203380.1
ACSL6 variant 1/NM_015256.2 variant 2/NM_001009185.1
variant 4/DQ083030
variant 5/DQ083031
variant 3/BC047453.1
The numbers listed represent the GenBank accession numbers of the respective spliced transcript variants.BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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Human ACSL transcript variants (A) and gate domains (B) Figure 5
Human ACSL transcript variants (A) and gate domains (B). A: Schematic representation of the different known tran-
script variants. Exons are represented by empty boxes and alternative exons by filled boxes. Translation initiator AUG and Y/
F-Gate domain encoding exons are indicated. If known, a capitalized V indicates the first exon of each variant. Note that only 
the sequence of the Gate-domain region of ACSL1_v3 and ACSL6_v4 is known. See Results for details. B: Alignment of the 
Gate-domain motifs. The F and Y residues of the two Gate domains are boxed. Highly conserved residues are shaded. Note 
that more residues are conserved among human ACSL isoforms. Position of the first and last residues shown is indicated on 
the left and right, respectively. Note that only the Gate-domain region of ACSL1_v3 and ACSL6_v4 is known. For clarity, 
ACSL3 variant 1 and 2, and ACSL5 variant 2 and 3, which encode the same isoform, are annotated as ACSL3_v1v2 and 
ACSL5_v2v3, respectively.
A 
ACSL1  
ACSL3 
ACSL4 
ACSL5 
ACSL6 
B 
Hs.ACSL1_v1     (306)   KALPLSASDTHISYLPLAHIYEQLLK    (331)
Hs.ACSL3_v1v2 (314)   RIPELGEEDVYIGYLPLAHVLELSAE    (339)
Hs.ACSL4_v1     (264)   RIPGLGPKDTYIGYLPLAHVLELTAE    (289)
Hs.ACSL4_v2     (305)   RIPGLGPKDTYIGYLPLAHVLELTAE    (330)
Hs.ACSL5_v1     (347)   HAYEPTPDDVAISYLPLAHMFERIVQ    (372)
Hs.ACSL5_v2v3 (291)   HAYEPTPDDVAISYLPLAHMFERIVQ    (316)
Hs.ACSL6_v1     (331)   SQWAPTCADVHISYLPLAHMFERMVQ    (356)
Hs.ACSL1_v2     (306)   NTVNPCPDDTLISFLPLAHMFERVVE    (331)
Hs.ACSL6_v2     (331)   KVIFPRQDDVLISFLPLAHMFERVIQ    (356)
Hs.ACSL6_v4      (?)    -------DDVLISFLPLAHMFERVIQ     (?)
Hs.ACSL6_v5     (321)   KVIFPRQDDVLISFLPLAHMFERVIQ    (360)
Hs.ACSL1_v3      (?)    --------------------------      (?)
Hs.ACSL6_v3     (270)   --------------------------     (270)
v1 v2
v3 
v5
  AUG
V1 V3
 AUG2
V2
v1
V1V2
  AUG1       AUG2
v1v2v3
V1V2 V3
 AUG2
v3 
V5
v1
v2v4v5
v3 
v4
V1V2
v1 
 AUG
AUG1
F-Gate Y-Gate
F-Gate Y-Gate
Y-Gate
Y-Gate
Y-Gate
AUG1
V1V2BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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nophilic leukemia [10] and a patient with atypical CML
[11].
In the plasma membrane of adult red cells, the function of
ACSL6 is activation of long-chain acyl groups for remode-
ling of lipids and acylation of proteins. In contrast, the
Gate (A) and linker (B) domains of human acyl-CoA synthetase family members Figure 6
Gate (A) and linker (B) domains of human acyl-CoA synthetase family members. The Y residue of the Gate 
domain for long and very-long-chain ACS is boxed. The D and G residues of the Linker domains are boxed. GenBank accession 
numbers for short, medium, long and very-long chain are indicated on the left. The Gate domain of BG1 is of the long-chain 
type but its Linker is of the short-medium type. Lipidosin is a soluble ACS very-long-chain isoform found in brain tissue and is 
known to have a broader substrate range than other very-long ACS [17, 18].
A 
         P-Loop               Gate 
NP_003636    TSGTTGLPKAAMITHQRIWYGTGL----T-FVSGLKADDVIYITLPFYHSAALLIGIHGCIVAGATL 
AAH57770     TSGTTG----------------------------------------------------------ATL 
NP_054750    TSGTTGLPKAAVISQLQVLRGSAV----L-WAFGCTAHDIVYITLPLYHSSAAILGISGCVELGATC 
NP_077306    TSGTTGLPKAARISHLKILQCQGF----Y-QLCGVHQEDVIYLALPLYHMSGSLLGIVGCMGIGATV 
NP_036386    TSGTTGLPKPAILTHERVLQMSKM----L-SLSGATADDVVYTVLPLYHVMGLVVGILGCLDLGATC  Very long
NP_005085    TSGTTGLPKAAIVVHSRYYRMAAL---VY-YGFRMRPNDIVYDCLPLYHSAGNIVGIGQCLLHGMTV 
NP_940982    TSGTTGLPKAAIVVHSRYYRMAAF---GH-HAYRMQAADVLYDCLPLYHSAGNIIGVGQCLIYGLTV 
NP_055977    TSGTTGNPKGVMLSQDNITWTARYGSQAGDIRPAEVQQEVVVSYLPLSHIAAQIYDLWTGIQWGAQV 
ACSL1_v1     TSGTTGNPKGAMVTHRNIVSDCSAFVKATEKALPLSASDTHISYLPLAHIYEQLLKC-VMLCHGAKI 
ACSL5_v1     TSGTTGDPKGAMITHQNIVSNAAAFLKCVEHAYEPTPDDVAISYLPLAHMFERIVQA-VVYSCGARV 
ACSL6_v1     TSGTTGNPKGAMLTHGNVVADFSGFLKVTESQWAPTCADVHISYLPLAHMFERMVQS-VVYCHGGRV  Long 
ACSL6_v3     TSGTTGNPKGAMLTHGNVVADFSGFLKVTE------------------------------------- 
ACSL3_v1     TSGSTGLPKGVMISHSNIIAGITG---MAERIPELGEEDVYIGYLPLAHVLELSAEL-VCLSHGCRI 
ACSL4_v1     TSGSTGRPKGVMMHHSNLIAGMTG---QCERIPGLGPKDTYIGYLPLAHVLELTAEI-SCFTYGCRI 
NP_001010845 TSGTSGLPKMAEHSYS-SLGLKAK---MDAGWTGLQASDIMWTISDTGWILNILCSLMEPWALGAC- 
NP_443188    TSGTTGFPKMAKHSHGLALQPSFP---GSRKLRSLKTSDVSWCLSDSGWIVATIWTLVEPWTAGCT-   Medium 
NP_060358    TSGTTGAPKMVEHSQSSYGLGFVA---SGRRWVALTESDIFWNTTDTGWVKAAWT-LFSAWPNGSC- 
NP_005613    TSGTSGYPKMTAHTHSSFGLGLSV---NGRFWLDLTPSDVMWNTSDTGWAKSAWSSVFSPWIQGAC- 
NP_061147    TSGSTGKPKGVVHTVGGYMLYVAT---TFKYVFDFHAEDVFWCTADIGWITGHSYVTYGPLANGATS 
NP_644803    TSGSTGKPKGVVHTVGGYMLYVAT---TFKYVFDFHAEDVFWCTADIGWITGHSYVTYGPLANGATS   Short 
NP_115890    TSGSTGMPKGIVHTQAGYLLYAAL---THKLVFDHQPGDIFGCVADIGWITGHSYVVYGPLCNGATS 
B 
              Linker 
NP_003636      LYFNSGDLLMVDHENFIYFHDRVGDTFRW 
AAH57770       LYFNSGDLLMVDHENFIYFHDRVGDTFRW 
NP_054750      VYLNTGDLIVQDQDNFLYFWDRTGDTFRW 
NP_077306      VFFNTGDLLVCDDQGFLRFHDRTGDTFRW   Very long-Chain 
NP_036386      VYYNTGDVLAMDREGFLYFRDRLGDTFRW 
NP_005085      QAYLTGDVLVMDELGYLYFRDRTGDTFRW 
NP_940982      SAYLSGDVLVMDELGYMYFRDRSGDTFRW 
NP_055977      -WLHTGDAGRLDADGFLYITGRLKELIIT 
ACSL1_v1       -WLHTGDIGKWLPNGTLKIIDRKKHIFKL 
ACSL5_v1       -WLHTGDIGRWLPNGTLKIIDRKKNIFKL 
ACSL6_v1       -WLHTGDIGKWLPAGTLKIIDRKKHIFKL   Long-Chain 
ACSL6_v3       -WLHTGDIGKWLPAGTLKIIDRKKHIFKL 
ACSL3_v1v2     RWLCTGDIGEFEPDGCLKIIDRKKDLVKL 
ACSL4_v1       RWFCTGDIGEFHPDGCLQIIDRKKDLVKL 
NP_001010845   DFWLLGDRGIKDEDGYFQFMGRADDIINS 
NP_443188      DFYNTGDRGKMDEEGYICFLGRSDDIINA 
NP_060358      DFYITGDRARMDKDGYFWFMGRNDDVINS   Medium-Chain 
NP_005613      NFYITGDRGYMDKDGYFWFVARADDVILS 
NP_061147      GYYVTGDGCQRDQDGYYWITGRIDDMLNV 
NP_644803      GYYVTGDGCQRDQDGYYWITGRIDDMLNV   Short-Chain 
NP_1158902     GYYFTGDGAYRTEGGYYQITGRMDDVINI BMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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predominant functions of ACSL members found in inter-
nal membranes are fatty acid degradation and de novo
lipid synthesis. Not counting glycolipid species or other
minor lipids, more than 250 different phospholipid
molecular species have been characterized in the mem-
brane of the red cell [12]. The different products of ACSL6
appear to be in a dimeric state, thus formation of hetero-
dimeric complexes could produce enough variety to
account for the specificity and selectivity in fatty acid acti-
vation observed in this membrane. Studies of the rat
homologue indicate that ACSL6 is preferentially involved
in metabolism of docosahexaenoic acid, a poly-unsatu-
rated fatty acid highly enriched in the nervous system
[13]. We also reported that human ACSL6 is expressed in
brain tissue [2], which may suggest an important role of
this protein in the plasma membranes of neuronal cells
that experience rapid phospholipid turnover.
Conclusion
We have identified several novel forms of acyl-CoA syn-
thetase long-chain members that differ in their fatty acid
Gate domain, and provided evidence that swapping or
deletion of this domain appears to be conserved in all
mammalian ACSL members 1 and 6. We propose that a
Phe to Tyr substitution is the structural reason for the con-
served alternative splicing that affects these motifs. This
mechanism may lead to enzymes with different substrate
Conservation of the gate and linker motifs among ACSL homologs Figure 7
Conservation of the gate and linker motifs among ACSL homologs. A: Alignment of the nine Arabidopsis ACSL 
forms. Human ACSL6 spliced variant 1 and 2, and ACSL of Thermus thermophilus (ttACSL) indicated with an asterisk (*) are 
shown as references in the last three rows. B: Alignment of various forms of ACSL from different organisms. Abbreviations: 
Dm, Drosophila melanogaster (fly); Cj, Callithrix jacchus (marmoset); Pp, Pongo pygmaeus (orangutan); Cp, Cavia porcellus 
(guinea pig); Ss, Sus scrofa (pig); Gg, Gallus gallus (chicken); Xt, Xenopus tropicalis (frog); Xl, Xenopus laevis (frog); Em, Elegi-
nops maclovinus (fish); Gg, Gobionotothen gibberifrons (fish); Dd, Dictyostelium discoideum (slime mould).
A
            P-loop                    Gate                 Linker 
AAM28868.1  TSGTSGDPKGVVLTHQAVATFVVGMDLYMDQFEDKMTHDDVYLSFLPLAHILDRMNE     GVLKIIDRKKNLIKL
AAM28869.1  TSGTTGEPKGVILNNAAISVQVLSIDKMLEVTDRSCDTSDVFFSYLPLAHCYDQVME     GSMKIIDRKKNIFKL
AAM28870.1  TSGTTGDPKGVLLTNESIIHLLEGVKKLLKTIDEELTSKDVYLSYLPLAHIFDRVIE     GAMKIIDRKKNIFKL
AAM28871.1  TSGTTGDPKGVMISNESIVTLIAGVIRLLKSANEALTVKDVYLSYLPLAHIFDRVIE     GSMKIIDRKKNIFKL
AAM28872.1  TSGTTGDPKGVMISNESIVTITTGVMHFLGNVNASLSEKDVYISYLPLAHVFDRAIE     GSMKIIDRKKNIFKL
AAM28873.1  TSGTTGTPKGVVLTHANLIANVAG--SSFSV-KFFS--SDVYISYLPLAHIYERANQ     GRLKIIDRKKNIFKL
AAM28874.1  TSGTTGTPKGVVLTHGNLIANVAG--SSVEA-EFFP--SDVYISYLPLAHIYERANQ     GRLKIIDRKKNIFKL
AAM28875.1  TSGSTGLPKGVMITHGNLVATAAGVMKVVPKLDK----NDTYIAYLPLAHVFELEAE     GCLEVIDRKKDIVKL
AAM28876.1  TSGSTGLPKGVMMTHGNVLATVSAVMTIVPDLGK----RDIYMAYLPLAHILELAAE     GCLEIIDRKKDIVKL
HsACSL6_v1* TSGTTGNPKGAMLTHGNVVADFSGFLKVTES-QWAPTCADVHISYLPLAHMFERMVQ     GTLKIIDRKKHIFKL
HsACSL6_v2* TSGTTGNPKGAMLTHGNVVADFSGFLKVTEK-VIFPRQDDVLISFLPLAHMFERVIQ     GTLKIIDRKKHIFKL
ttACSL*     TTGTTGLPKGVVYSHRALVLHSLA---ASLVDGTALSEKDV  VLPVVPMFHVNAWCLP    GYVEIKDRLKDLIKS
B 
        P-loop          Gate               Linker 
NP_730369.1 (Dm)TSGTTGNPKGVMLTHGNVVAGVCSVILQMGDHRI-RAGDVMVSFLPLAHMFERCCE  GTLRIIDRRKHIFKL
AAG10398.2  (Cj)TSGTTGNPKGALITHRNVVSDCSAFVKMTEKVLALNASDTHISFLPLAHMYEQLML  GTLKIIDRKKHIFKL
CAH92092.1  (Pp)TSGTTGNPKGAMVTHRNIVSDCSAFVKATENTVNPCPDDTLISFLPLAHMFERVVE  GTLKIIDRKKHIFKL
AAF91295.1  (Cp)TSGTTGNPKGAMITHKNVVSDCSAFVKATEKALVLNASDIHISFLPLAHMYEQLLQ  GTLKIIDRKKHIFKL
AAT79534.1  (Ss)TSGTTGNPKGAMITHRNVVSDCSAFVKVTDKTFSPSSDDTLISFLPLAHMFERVVE  GTLKIIDRKKHIFKL
NP_001012596(Gg)TSGTTGNPKGAMITHKNIVSNSSAFLKTTEKTFIPTPEDVLISFLPLAHMFERIVE  GTLKIIDRKKHIFKL
NP_001006830(Xt)TSGTTGNPKGAMLSHKNIVSNSAGFMKVTEDLMFPSTQDVLISFLPLAHMFERVVE  GTLKIIDRKKHIFKL
AAH46740.1  (Xl)TSGTTGNPKGAMLSHKNIVSNSAGFMKVTEDLMFPSTQDVLISFLPLAHMFERVVE  GTLKIIDRKKHIFKL
AAH43756.1  (Xl)TSGTTGNPKGAMLSHKNIVSNSAGFMKVTEDFMFPSTQDVLISFLPLAHMFERVVE  GTLKIIDRKKHIFKL
AAN38754.1  (Em)TSGTTGNPKGAMLTHGNVISNTAAFIRITETILKPSAKDVLISFLPLAHMFERVVE  GCLKITDRKKHIFKL
AAK07471.1  (Gg)TSGTTGNPKGAMLTHGNVISNTAAFIRITEAILKPSTEDCLISFLPLAHMFERVVE  GCLKITDRKKRIFKL
NP_609696.1 (Dm)TSGTVGMPKAVMLSHDNLVFDTKSAAAHMQDIQV--GKESFVSYLPLSHVAAQIVI  GNLIISGRLKELIIT
DDB0231574  (Dd)TSGTTGPPKGVMITHKNLTSVVCA---VS-DFIKVYDTDVHYSYLPYAHVLERVVV  GSLSIVDRKKNIFKL
DDB0191105  (Dd)TSGSTGNPKGVMLTHTNMVSEVAG---ANFSPAGVIPEDVHMSYLPLAHSFERAFD  GTLSIIDRKKNIFKLBMC Molecular Biology 2006, 7:21 http://www.biomedcentral.com/1471-2199/7/21
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specificity necessary to maintain the complex fatty acid
composition of membranes.
Methods
DNA manipulations
PCR amplifications were performed from cDNAs of CD34
positive progenitors, K562 cells, fetal blood cells, reticulo-
cytes and placenta [2]. Amplification of the Gate-domain
regions of ACSL1 and ACSL6 were performed with the fol-
lowing set of primers:
Hs-ACSL6-902 (5'-ACTGTGGCCAAGAGAATCACCAG-
GCTCC-3'), Hs-ACSL6-1266/rev (5'-GTACATCCGGT-
TCAGCAGTCGTGGGACC-3') and Hs-ACSL1-937 (5'-
CCTGGGAAGAGCCAACAGACGGAAGCCC-3'), Hs-
ACSL1-1294/rev (5'-CCGGTTCAGCAGTCTTGGAAC-
CACGGGG-3').
The PCR amplifications were performed with 1 μl of
cDNA with Expand High-Fidelity Taq polymerase accord-
ing to the manufacturer instructions (Roche). The anneal-
ing temperature was 66°C for ACSL1  and 64°C for
ACSL6. The reaction conditions were as follows: one cycle
at 95°C for 2 min, 40 cycles at 94°C for 30 s, 64°C or
66°C for 60 s, 72°C for 30 s, and one cycle at 72°C for 10
min. The PCR fragments (≈350 bp), isolated and purified
from 1.5% agarose gels, were cloned with the Zero-Blunt
PCR cloning kit (Invitrogen). Single colony transformants
were selected on Kanamycin 50 μg/ml Luria-Broth plates.
Two μl of an overnight grown culture were used directly
for PCR amplification of the insert. Amplifications were
done using M13(-20)fwd and M13(-27)rev primers with
Promega Taq polymerase in buffer B according to the
manufacturer instruction. First, 2 μl of cells were lysed and
proteins denatured at 95°C for 10 min. in 50 μl of water.
Then, 50 μl of doubled-concentrated PCR reagent mixture
(25 ng of each primer, 200 μM dNTPs, 1 unit Taq, buffer
B 2×) was added, and amplification reactions were done
at 94°C for 60 s, 25 cycles at 94°C for 30 s, 47°C for 30 s,
72°C for 30 s, and one cycle at 72°C for 10 min. In each
case, the single PCR product was isolated with the PCR
purification kit of Qiagen and was sequenced. 5'-RACE
PCR of human Leukaemia, Chronic Myelogeneous Mara-
thon-Ready cDNA (K562 cells) (Clontech Laboratories,
Inc.) for isolation of ACSL1_v1 was performed with
primer Hs. ACSL1-1294/rev, and AP1 according to the
manufacturer instructions. Full-length RACE PCR of retic-
ulocyte cDNA for isolation of ACSL6_v5 was performed as
previously described [2].
Expression and immunodetection of ACSL6
ACSL6 isoforms were cloned by PCR into vector pET28a
(Novagen) with a unique in-frame hexahistidine tag at the
N-terminus, and were transformed into E. coli host
BL21(DE3) cells. Cloning of ACSL6_v2 has been previ-
ously described [2]. Coding sequence of variant 3 was
obtained by PCR amplification of the cDNA clone
MGC:48352 [GenBank: BC047453] obtained from Amer-
ican Type Collection Center. The 1,889 bp fragment was
amplified by a primer set introducing a restriction site for
NheI at the 5' end and HindIII at the 3' end, and was then
cloned with the Zero-Blunt PCR cloning kit of Invitrogen
according to the manufacturer instructions, to yield plas-
mid pFK128. Forward primer was L6-v3-Nhe (5'-ACTAT-
AGCTAGCCAGACACAGGAGATCCTG-3') and the reverse
primer was L6-v3-Hind (5'-CTATGCAAGCTTCACAT-
GGAGATTGAGTA-3') (NheI and HindIII sites are under-
lined). The 1.9 kbp NheI-HindIII fragment of pFK128 was
cloned in frame into pET28a opened by NheI and HindIII,
to yield plasmid pFK129. ACSL6_v2 (pKTM99) and
ACSL6_v3 (pFK129) plasmids were transformed into
chemically competent BL21(DE3) cells and selected on
kanamycin (30 μg/ml) Luria-Bertani plates. Cells were
grown at 37°C in liquid medium with kanamycin to an
O.D.600 nm of 0.5 to 0.6 and grown for another 2 hours
in the absence or presence of 100 μM of IPTG. Cells were
chilled on ice and harvested by centrifugation at 6,000 g
for 5 min at 4°C. The medium was discarded and pellets
were quickly frozen in dry-ice and stored at -80°C. Total
protein extracts were obtained by sonication of thawed
pellets suspended in Buffer A [Tris-HCl 50 mM, pH 8.0;
EDTA 5 mM; NaCl 0.3 M; DTT 5 mM; PMSF 0.1 mM]
using 3 pulses of 20 s on ice. The lysates were cleared by
centrifugation at 8,000 g for 20 min at 4°C. Most of the
fusion protein was lost during this step and was found in
inclusion bodies. The same was true when cells were
grown at 25°C [8]. Less than 10% was still present in the
cleared lysate. To prepare the membrane and soluble frac-
tions, total extracts were subjected to centrifugation at
100,000 g for 60 min at 10°C. The supernatant repre-
sented the soluble fraction. The pellet was suspended in
buffer A and represented the membrane fraction. Protein
samples, about 10 μg, were denatured for 20 min at 37°C
in 20 μl SDS-PAGE loading buffer 1× and were loaded in
each lane of a SDS-PAGE 7.5% gel. The high molecular
band (130 kDa) (Figure 3A), also observed on 2D-gels,
was not detected when the protein samples were boiled
before loading and/or when the samples were further
diluted in SDS-PAGE loading buffer. Rat ACSL6-FLAG
fusion proteins [8] showed the same migration pattern
that human ACSL6-His tag proteins do under these condi-
tions. Immuno-detection was performed with a commer-
cial anti-histidine HRP-conjugated antibody (INDIA-
HisProbe-HRP antibody, Pierce) (Figure 3A) and with a
peptide-raised ACSL6 antibody (Figure 3B) detected with
a HRP-conjugated goat anti-rabbit IgG (Pierce). Each anti-
body was diluted a thousand fold. HRP detection was per-
formed with ImmonoPure DAB (Pierce) according to the
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Sequence analysis
Sequence alignments were generated with MUTALIN [14].
Sequences were retrieved from RefSeq [15,16], and Gen-
Bank databases. Exon and intron definitions of ACSL
genes were obtained using Evidence Viewer, and Model
Maker available at the Map Viewer page of each gene.
Accession numbers
The nucleotide sequences for ACSL1 variant 1, ACSL1 var-
iant 3, ACSL6 variant 4 and ACSL6 variant 5 have been
deposited in the GenBank database under GenBank
Accession Number DQ083029, DQ083028, DQ083030
and DQ083031, respectively.
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